Gynecological Health

Matrix Health and Care Secures Patent for Advanced Pelvic Assessment Device

Matrix Health and Care has been granted a patent from the USPTO for Matrix, an innovative self-use pelvic assessment tool aimed at enhancing gynecological examinations. Distinct from traditional speculums, Matrix emphasizes patient comfort and control, allowing for self-administration in clinical settings and integrating real-time data transmission for clinical evaluation and research. The patent marks a significant milestone for Matrix Health & Care…

Vivoo Unveils New At-Home UTI Test at CES 2024

Vivoo, a wellness app renowned for offering personalized nutrition and lifestyle guidance through at-home urine tests, has introduced a new at-home Urinary Tract Infection (UTI) testing product at CES 2024. This recent addition, recognized as a CES 2024 Innovation Awards honoree, delivers results within minutes and is aimed at simplifying the process of health monitoring and facilitating quicker connections with healthcare professionals.…

ASPIVIX Receives CE Mark for Carevix, Its Device to Lower IUD Procedural Pain

Aspivix, a company specializing in women’s health technology, has recently received CE Mark approval for its Carevix device, indicating its compliance with European health, safety, and environmental protection standards. This approval allows for the commercial use of Carevix in European countries. Carevix is designed to reduce pain during transcervical procedures, such as the placement of Intrauterine Devices (IUDs). It operates using a…

Endometrial Cancer Diagnostics Company MiMARK Secures €4.22M in Seed Funding

MiMARK Diagnostics, a company specializing in women’s health, has completed its first seed funding round, raising €4.22M. The funds are intended to advance their work in gynecological diagnostics, focusing on the use of gynecological fluids as a non-invasive source for biomarker detection. The company received €1.5M from EIT Health back in 2021. MiMARK is developing in vitro diagnostic solutions for managing gynecological…

Gynesonics Announces $67M Financing to Expand Commercialization of Its Sonata Procedure Targeting Uterine Fibroids

Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that it has secured an incremental $42.5 million in financing (total of $67.2M inclusive of initial April 2023 financing). The round was led by existing Gynesonics investors Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new…

Health Canada Approves MYFEMBREE for the Treatment of Endometriosis and Uterine Fibroids

Health Canada has granted approval to MYFEMBREE for the management of pain related to endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The drug, a joint venture between Sumitomo Pharma Canada and Pfizer Canada, is an oral combination therapy meant to be taken once daily. Endometriosis and uterine fibroids are serious health issues affecting a significant portion of…

Daye and Lindus Health Launch Clinical Trial to Develop Diagnostic Tampon for At-home STI and HPV Testing

Gynae Health startup Daye and clinical trial company Lindus Health have launched a clinical trial for a Diagnostic Tampon designed to allow women and assigned female at birth (AFAB) individuals to conduct HPV and STI tests in their homes. Supporting Daye’s mission to close the gender health gap, its Diagnostic Tampon has the potential to transform women’s experience when being screened for…

Nesa Medtech’s Fibroid Mapping Reviewer Application Gains FDA Approval

Indian femtech company Nesa Medtech has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Fibroid Mapping Reviewer Application (FMRA). The Software as a Medical Device (SaMD) creates a 3D model of the uterus from ultrasound images, helping physicians diagnose and plan treatments for patients with symptomatic uterine fibroids. Uterine fibroids, also known as leiomyomas, are non-cancerous growths…